Cristina Falci

Cristina Falci

Auto-generated profile, based on publicly available information

Cristina Falci

Istituto Oncologico Veneto, IRCCS, Padova, Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2006
Verified
Journal Article
Closed access
LPLara Maria Pasetto
Lara Maria Pasetto
MFMaria Luisa Friso
Maria Luisa Friso
SPSalvatore Pucciarelli
Salvatore Pucciarelli
UBUmberto Basso
Umberto Basso
CFCristina Falci
Cristina Falci
Silvio MonfardiniSilvio Monfardini
Silvio Monfardini

30 August 2008
Verified
Journal Article
Closed access
LPLara Maria Pasetto
Lara Maria Pasetto
CFCristina Falci
Cristina Falci
UBUmberto Basso
Umberto Basso
GGGiampietro Gasparini
Giampietro Gasparini
MDMario D'andrea
Mario D'andrea
Silvio MonfardiniSilvio Monfardini
Silvio Monfardini

3 March 2016 in Expert Review of Quality of Life in Cancer Care
Verified
Journal Article
Closed access
EMEleonora Mioranza
Eleonora Mioranza
CFCristina Falci
Cristina Falci
MDMaria Vittoria Dieci
Maria Vittoria Dieci
VGValentina Guarneri
Valentina Guarneri
PCPierfranco Conte
Pierfranco Conte
Although endocrine therapy (ET) plays a crucial role in the adjuvant treatment of ER-positive breast cancer, a significant proportion of patients discontinue treatment early because of toxicity. In recent years a number of papers have attempted to quantify the impact of adjuvant ET on the quality-of-life (QOL) of the patient. The aim of this present review is to report the results of prospective trials that have measured the effect of adjuvant ET on the QOL in breast cancer patients. In most trials a great discrepancy has emerged between the magnitude of treatment-related symptoms and a drop in different QOL domains. In fact, the average change of QOL scores, if present, was unexpectedly small. Moreover, aromatase inhibitors were shown to have an unfavorable profile when compared to tamoxifen, in the up-front or switched schedule, or to placebo, in the extended strategy. Further studies are warranted to implement more sensitive and largely accepted QOL instruments.

2 November 2007
Verified
Journal Article
Closed access
LPLara Maria Pasetto
Lara Maria Pasetto
CFCristina Falci
Cristina Falci
UBUmberto Basso
Umberto Basso
GGGiampietro Gasparini
Giampietro Gasparini
MDMario D'andrea
Mario D'andrea
Silvio MonfardiniSilvio Monfardini
Silvio Monfardini

11 November 2006
Verified
Journal Article
Closed access
LPLara Maria Pasetto
Lara Maria Pasetto
ABAlberto Bortolami
Alberto Bortolami
CFCristina Falci
Cristina Falci
GSGiulietta Sinigaglia
Giulietta Sinigaglia
Silvio MonfardiniSilvio Monfardini
Silvio Monfardini

18 July 2008
Verified
Journal Article
Closed access
LPLara Maria Pasetto
Lara Maria Pasetto
CFCristina Falci
Cristina Falci
ERElisa Rizzo
Elisa Rizzo
GSGian Luca De Salvo
Gian Luca De Salvo
GGGiampietro Gasparini
Giampietro Gasparini
Silvio MonfardiniSilvio Monfardini
Silvio Monfardini